All In Biotech

NDA 214278 · Dexcel

Esomeprazole Magnesium

Esomeprazole Magnesium · Oral

Discontinued

Last checked: Nov 20, 2026Latest source record: May 11, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Oct 20, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

522

102 Phase 3, 23 recruiting

FAERS reports

62,630

55,187 serious, 6,327 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 20, 2020 Original approval · Type 3 - New Dosage Form LetterReview
1 products under this application
  • ESOMEPRAZOLE MAGNESIUM · ESOMEPRAZOLE MAGNESIUM EQ 20MG BASE · TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Esomeprazole" as an intervention, any sponsor and status, largest first.

All 522 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease5,036
  • acute kidney injury4,745
  • nausea4,386
  • diarrhoea4,167
  • headache3,799
  • fatigue3,798
  • drug ineffective3,635
  • off label use3,621
  • dyspnoea3,491
  • pain2,945
  • vomiting2,920
  • arthralgia2,767

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004415
2005501
2006349
2007528
2008958
2009768
2010849
2011727
2012798
2013992
20141,148
20151,661
20162,297
20172,675
20185,567
20197,259
20205,076
20214,578
20225,194
20235,435
20245,621
20255,372
20263,861

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Esomeprazole Magnesium (Esomeprazole Magnesium)

2024 spending

$124M

Beneficiaries

741,842

2,912,529 claims

Per beneficiary

$168

$0.64 per unit

View as table
YearSpending
2020$280,364,887
2021$252,578,062
2022$236,941,286
2023$172,008,188
2024$124,296,527

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 777 on PubMed

Sponsor: Dexcel

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.